Expertise in
7
conditions

Jordi Bruix

Barcelona, CT, ES 
Expertise in
7
conditions
Barcelona, CT, ES 

Overview

Jordi Bruix practices practicing medicine in Barcelona, Spain.

Bruix is highly rated in 7 conditions, according to our data. Their clinical expertise encompasses Liver Cancer, Cholangiocarcinoma (Bile Duct Cancer), Hepatitis C, Liver Transplant, and Hepatectomy.

They are actively involved in clinical research, co-authoring 207 peer reviewed articles and participating in 2 clinical trials.

Locations

Barcelona, CT, Spain
Other Locations
Madrid, MD, Spain
Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
Enrollment Status: Completed
Publish Date: June 17, 2026
Intervention Type: Genetic
Study Phase: Phase 1
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: May 09, 2025
Intervention Type: Device, Drug
Study Drug: Cisplatin-Gemcitabine
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

207 Total Publications

Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].
Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].
Journal: Journal of hepatology
Published: April 05, 2026

Frequently Asked Questions about Jordi Bruix

Is Jordi Bruix a top-rated expert for Liver Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Jordi Bruix is classified as an Elite expert for Liver Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jordi Bruix participate in research or clinical trials?

Yes. Jordi Bruix has published 207 articles and abstracts on conditions like Liver Cancer. You can view a list of Jordi Bruix's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Bruix's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile